2024
Surveillance with dual noninvasive testing for acute cellular rejection after heart transplantation: Outcomes from the Surveillance HeartCare Outcomes Registry
Khush K, Hall S, Kao A, Raval N, Dhingra R, Shah P, Bellumkonda L, Ravichandran A, Van Bakel A, Uriel N, Patel S, Pinney S, DePasquale E, Baran D, Pinney K, Oreschak K, Kobulnik J, Shen L, Teuteberg J. Surveillance with dual noninvasive testing for acute cellular rejection after heart transplantation: Outcomes from the Surveillance HeartCare Outcomes Registry. The Journal Of Heart And Lung Transplantation 2024, 43: 1409-1421. PMID: 38759766, DOI: 10.1016/j.healun.2024.05.003.Peer-Reviewed Original ResearchAcute cellular rejectionIncidence of acute cellular rejectionBiopsy rateGene expression profilesNon-invasive testsMolecular testingDd-cfDNACellular rejectionGraft dysfunctionHeart transplantationFollow-up testing ratesIncidence of graft dysfunctionLow biopsy rateFollow-up biopsiesPositive likelihood ratioNon-invasive surveillanceBiopsy dataClinical decision-makingExcellent survivalOutcomes RegistryFollow-upLow incidenceBiopsyPositive groupDual testing
2023
Role of ascorbic acid in cardiac allograft vasculopathy
Chang A, Martin K, Colvin M, Bellumkonda L. Role of ascorbic acid in cardiac allograft vasculopathy. Clinical Transplantation 2023, 37: e15153. PMID: 37792313, DOI: 10.1111/ctr.15153.Peer-Reviewed Original ResearchConceptsCardiac allograft vasculopathySmooth muscle cell apoptosisAllograft vasculopathyDisease processMuscle cell apoptosisSignificant long-term morbidityCell apoptosisProgressive fibroproliferative diseasePost-transplant carePost-transplant managementLong-term morbiditySmall clinical trialsChallenging disease processVascular smooth muscle cell apoptosisHeart transplantationCAV progressionEndothelial dysfunctionRapamycin inhibitorsClinical trialsIntimal thickeningPrevents developmentInterferon γRodent modelsIntimal hyperplasiaMTOR inhibitors
2022
Impact of Donor Characteristics on AlloSure Scores
Alam A, Uriel N, Shah K, Shah P, Zeng J, Dhingra R, Bellumkonda L, Pinney S, DePasquale E, Hall S. Impact of Donor Characteristics on AlloSure Scores. The Journal Of Heart And Lung Transplantation 2022, 41: s337. DOI: 10.1016/j.healun.2022.01.1398.Peer-Reviewed Original ResearchEarly post-transplant periodPost-transplant periodRecipient variablesLow-level donor-specific antibodyOngoing myocardial injuryDonor-specific antibodiesFurther prospective studiesCause of deathDiverse patient cohortAllograft injuryImmunologic variablesInduction therapyCohort patientsHeart transplantationImmunosuppressive therapyCMV statusStable patientsMyocardial injuryProspective studyClinical eventsComparator groupPatient cohortASES scoresDonor ageInclusion criteria
2018
Role of Class I and Class II Panel Reactive Antibodies in Predicting Post-Heart Transplant Rejection and Survival in the Current Era.
Kunnirickal S, Bellumkonda L. Role of Class I and Class II Panel Reactive Antibodies in Predicting Post-Heart Transplant Rejection and Survival in the Current Era. Journal Of Cardiac Failure 2018, 24: s112. DOI: 10.1016/j.cardfail.2018.07.414.Peer-Reviewed Original ResearchPanel reactive antibodyClass II antibodiesClass II panel reactive antibodiesClass I antibodiesYear of transplantationII antibodiesLong-term survivalClass IRecipient ageReactive antibodiesI antibodiesElevated panel reactive antibodyOverall long-term survivalLonger waitlist timesPrior heart transplantationLong-term mortalityMethods Retrospective analysisSame prognostic implicationsClass 2 antibodiesHeart transplantationHLA mismatchesHazard ratioIschemic timeHeart transplantPrognostic role